Skip to main content
Terug
RLAY logo

Relay Therapeutics, Inc.

Datakwaliteit: 100%
RLAY
NASDAQ Healthcare Biotechnology
€ 9,82
▼ € 0,09 (-0,91%)
Marktkapitalisatie: 1,76B
Dagbereik
€ 9,69 € 10,20
52-Weeksbereik
€ 1,78 € 11,49
Volume
2.001.523
50D / 200D Gem.
€ 8,91 / € 6,19
Vorige Slotkoers
€ 9,91

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -6,4 0,4
P/B 3,1 2,9
ROE % -41,1 3,8
Net Margin % -1800,6 3,9
Rev Growth 5Y % 50,1 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 50,05% annually over 5 years — strong growth
Debt/Equity of 0,06 — conservative balance sheet
Negative free cash flow of -235,87M
PEG of 0,17 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,39%
Capital efficient — spends only 2,67% of revenue on capex

Groei

Revenue Growth (5Y)
50,05%
Revenue (1Y)53,44%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-41,12%
ROIC-37,87%
Net Margin-1800,58%
Op. Margin-1971,59%

Veiligheid

Debt / Equity
0,06
Current Ratio22,61
Interest Coverage0,00

Waardering

P/E Ratio
-6,35
P/B Ratio3,10
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 53,44% Revenue Growth (3Y) -22,47%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 50,05% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 15,36M Net Income (TTM) -276,48M
ROE -41,12% ROA -44,50%
Gross Margin 76,83% Operating Margin -1971,59%
Net Margin -1800,58% Free Cash Flow (TTM) -235,87M
ROIC -37,87% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,06 Current Ratio 22,61
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -6,35 P/B Ratio 3,10
P/S Ratio 114,30 PEG Ratio 0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,76B Enterprise Value 1,70B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 15,36M 10,01M 25,55M 1,38M 3,03M
Net Income -276,48M -337,71M -341,97M -290,51M -363,87M
EPS (Diluted) -1,61 -2,36 -2,79 -2,59 -3,82
Gross Profit 11,80M 10,01M 25,55M 1,38M 3,03M
Operating Income -302,74M -372,47M -373,00M -299,28M -364,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 621,33M 871,30M 843,98M 1,10B 1,01B
Total Liabilities 54,27M 93,50M 91,98M 149,55M 110,64M
Shareholders' Equity 567,06M 777,79M 752,00M 950,22M 897,81M
Total Debt 32,46M 48,50M 53,47M 57,74M 22,90M
Cash & Equivalents 84,02M 124,29M 143,74M 998,92M 280,12M
Current Assets 578,28M 809,20M 770,10M 1,02B 976,24M
Current Liabilities 25,58M 50,73M 30,27M 63,71M 24,32M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#68 of 146
47

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026